Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
The pharma giant is expanding its site in Pleasant Prairie, Wisconsin after acquiring the facility from Nexus in April.
Deal-Making
Danish pharma giant Novo Nordisk will acquire Novavax’s manufacturing facility in the Czech Republic.
KBI will use its monoclonal antibody (mAb) platform to produce ATI’s lead candidate for clinical testing.
Facilities & Capacity
The five Chinese companies targeted by the US government’s BIOSECURE Act receive a proverbial stay of execution.
“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.
Global Markets
The five Chinese companies targeted by the US government’s BIOSECURE Act receive a proverbial stay of execution.
Fostering a culture of compliance and quality alignment with Western regulators is vital for India's biomanufacturing growth: “If you are open for business every day, you have to be ready for inspection every day.”
Regulations
Pfizer, Merck & Co., and Moderna remain upbeat over future dealings with the US government despite President-elect Trump telling vaccine-sceptic and alternative-medicine proponents to “go wild on health.”
While much talk at CPHI Milan centered on the potential impact of BIOSECURE, other US policies – particularly the Inflation Reduction Act (IRA) – are proving a boon for Indian CDMOs.
Content Spotlight
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Therapeutic Class
“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.
To reach its full potential, India must drop its ‘colonial mindset,’ says Biocon COO.
Upstream & Downstream Processing
“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.
“Biotech funding is improving. It's not robust, but it's improving,” says Thermo Fisher’s CEO amid numerous reasons to be cheerful in an ever-changing world.